CHRONIC HEPATITIS B

This study looks at whether a medicine called peginterferon alfa, alone or with other antivirals, can clear the hepatitis B surface antigen from the blood. A total of 10,000 adults aged 18-65 who have used interferon before and still have low antigen levels will take the treatmen…

This phase 2 trial tests an injection called AHB-137 in adults with chronic hepatitis B who have not yet received treatment. The study compares AHB-137 to a placebo to see if it can lower the amount of hepatitis B virus in the blood and reduce a key marker of infection (HBsAg). P…

This Phase 2 trial tests an injection called AHB-171 in 138 people with chronic hepatitis B. The goal is to see if it can lower hepatitis B surface antigen and viral DNA to very low levels, potentially leading to a functional cure. Participants include those who have never been t…

This early-phase study tests a new injectable drug called AHB-171 in 144 adults with chronic hepatitis B. The main goals are to check the drug's safety and how the body processes it. Some participants will also take standard oral antivirals. The study is not yet recruiting.

This study tests an experimental injection called HRS-5635 in adults with chronic hepatitis B whose virus is already controlled by daily pills. The goal is to see if the injection can help the body clear the virus so patients can safely stop all hepatitis B medications. About 540…

This early-stage study tests a single injection of AHB-137 in 32 people with chronic hepatitis B, some with mild to moderate liver dysfunction and some with normal liver function. Researchers will measure how the drug moves through the body and check for safety issues. The goal i…

This early-stage trial is testing a new drug called ACT500 in 24 people who have both fatty liver disease and chronic hepatitis B. The main goal is to check the drug's safety and how the body processes it at different doses. Participants will take ACT500 or a placebo daily, and r…

This phase 3 trial tests a new drug called GST-HG141 (Nairecovir) combined with standard antivirals in 576 adults with chronic hepatitis B. Participants have already completed 48 weeks of treatment in an earlier study. The goal is to see if the combination is safe and helps keep …

This study tests an AI-powered assistant (Union-Agent) designed to encourage people with chronic hepatitis B who have been diagnosed but not yet treated to start antiviral medication. The study will enroll 2000 adults in China who are eligible for treatment but haven't started. T…

This study tests whether giving two antiviral drugs—entecavir followed by pegylated interferon—can help children aged 3 to 6 with chronic hepatitis B achieve a functional cure (clearing the virus from the blood). About 80 children will be randomly assigned to receive either entec…

This study tests whether adding pegylated interferon to entecavir helps young children (ages 3-6) with chronic hepatitis B achieve a functional cure, meaning the virus becomes undetectable. Sixty children will receive either entecavir alone or entecavir followed by the combinatio…

This Phase 3 trial tests an injection called TVAX-008 for people with chronic hepatitis B. About 630 adults who have been on antiviral therapy for at least 6 months will receive either TVAX-008, a placebo, or an active comparator. The goal is to see if the treatment can clear hep…

This study will offer free hepatitis B testing to nearly 240,000 adults in Phichit, Thailand, who were born before 1992 and may have been infected before vaccines were available. Those who test positive will receive care and daily medication to control the virus and prevent liver…

This early-stage trial tests a new therapeutic vaccine (Hepadvax) in 40 adults with chronic hepatitis B. The vaccine is designed to boost the immune system to control or possibly clear the virus. Researchers will monitor safety, viral load, and immune responses compared to a stan…

This study will follow 352 pregnant women with chronic hepatitis B to see how often their liver enzymes rise after giving birth. Researchers want to find out what factors predict these spikes, especially comparing those who took antiviral drugs during pregnancy to those who did n…

This study looks at how the hepatitis B virus changes over time in people taking antiviral drugs. Researchers will analyze blood samples from 700 adults in Turkey to see if the virus becomes resistant to treatment. The goal is to help doctors choose the best medications for each …

This study will compare a new handheld device to the standard iLivTouch system for measuring liver stiffness and fat in 224 adults with chronic liver disease. Participants will be tested with both devices while lying down and sitting. The goal is to see if the handheld device is …